---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-001392"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2025-01-07T23:59:59+00:00"
generated_at: "2026-05-28T08:11:54.782498+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# CorMedix reports preliminary Q4 2024 net revenue ~$31M, FY ~$43M; Q4 Adj EBITDA >$12M

## Summary
- Q4 2024 prelim unaudited net revenue ~$31M; FY 2024 ~$43M; Q4 Adj EBITDA >$12M.
- Open purchase orders >$25M for Q1 2025 delivery; shipping DefenCath to all three MDO customers.
- LDO implementation targeted H1 2025; aims for 4,000 patients in H2 2025.
- Expanded inpatient deployment with Syneos Health in Q1 2025; field team reorganized, some roles eliminated.
- FY 2025 opex guidance $72-78M (excl non-cash/one-time); cash & investments ~$52M at Dec 31, 2024.

## SEC filing metadata
- accession: 0001213900-25-001392
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2025-01-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390025001392/0001213900-25-001392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390025001392/ea0226957-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-001392
- JSON: https://secwatch.observer/filing/0001213900-25-001392.json
- Plain text: https://secwatch.observer/filing/0001213900-25-001392.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.